细胞周期进展评分可能改善新诊断前列腺癌患者的当前风险评估
该研究在新诊断前列腺癌并接受根治性前列腺切除术的52例患者中评估活检CCP评分(Prolaris)能否改善风险评估。CCP评分在单变量和多变量分析中均为高风险前列腺癌的显著预测因子,与EAU临床风险评估联合可将风险归因准确率提高约10%至87.8%。CCP评分仅在单变量分析中为生化复发的显著预测因子。
要点
- Prolaris检测将7例高风险和13例中风险患者错误分类。
- CCP评分均值在不同病理风险组间存在显著差异:低风险-1.2、中风险-0.444、高风险0.208。
- CCP评分联合EAU临床风险评估使风险归因准确率提高约10%,达87.8%。
核心结论
- CCP评分可能为传统临床变量之外的新诊断前列腺癌风险评估提供重要新信息。
- 正确的风险归因对于为每位患者定制最佳治疗至关重要。
研究设计与样本
- 在52例新诊断前列腺癌并接受根治性前列腺切除术的患者中评估活检CCP评分。
- CCP评分计算为31个CCP基因的平均RNA表达,以15个管家基因标准化。
- 通过单变量和多变量分析评估CCP评分的预测能力,并与Ki-67水平及传统临床变量(前列腺特异性抗原、Gleason评分、分期、活检阳性针芯百分比)比较。
主要发现
- 尽管Prolaris检测在归因正确风险类别方面总体准确率良好,仍有7例高风险和13例中风险患者被错误分类。
- 方差分析显示,基于病理结果的不同风险类别间CCP评分均值存在显著差异:低风险-1.2、中风险-0.444、高风险0.208。
- CCP评分在单变量和多变量分析中均为高风险前列腺癌的显著预测因子,校正临床变量后仍显著。
- CCP评分联合欧洲泌尿外科学会临床风险评估使风险归因准确率提高约10%,达87.8%。
- CCP评分仅在单变量分析中为生化复发的显著预测因子。
局限性
- CCP评分仅在单变量分析中为生化复发的显著预测因子,多变量分析中不显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether cell-cycle progression (CCP)-score (Prolaris) can improve the current risk assessment in newly diagnosed prostate cancer (PCa) patients. CCP-score is a well-validated prognostic assay predictive of PCa death, biochemical recurrence, and progression. METHODS: We evaluated CCP-score at biopsy in 52 patients newly diagnosed with PCa who underwent radical prostatectomy. CCP-score was calculated as average RNA expression of 31 CCP genes, normalized to 15 housekeeping genes. The predictive ability of CCP-score was assessed in univariate and multivariate analyses, and compared to that of Ki-67 levels and traditional clinical variables including prostate-specific antigen, Gleason score, stage, and percentage of positive cores at biopsy. RESULTS: In spite of an overall good accuracy in attributing the correct risk class, 7 high-risk and 13 intermediate-risk patients were misclassified by the Prolaris test. On analysis of variance, mean CCP-score significantly differed across different risk classes based on pathologic results (-1.2 in low risk, -0.444 in intermediate risk, 0.208 in high risk). CCP-score was a significant predictor of high-risk PCa both on univariate and multivariate analyses, after adjusting for clinical variables. Combining CCP-score and the European Association of Urology clinical risk assessment improved the accuracy of risk attribution by around 10%, up to 87.8%. CCP-score was a significant predictor of biochemical recurrence, but only on univariate analysis. CONCLUSION: The CCP-score might provide important new information to risk assessment of newly diagnosed PCa in addition to traditional clinical variables. A correct risk attribution is essential to tailor the best treatment for each patient.
引用
- Oderda M, Cozzi G, Daniele L, et al. Cell-cycle Progression-score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients. Urology. 2016. PMID: 27894974. doi:10.1016/j.urology.2016.11.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。